PROGRAM. Educational Session: Genomics 15:00-17:00 Session Chair: Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

Size: px

Start display at page:

Download "PROGRAM. Educational Session: Genomics 15:00-17:00 Session Chair: Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada"

Sharlene Burke
6 years ago
Views:

1 Thursday, May 4 Educational Session: Genomics 15:00-17:00 Session Chair: Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada Molecular Tumor Board - Case Presentation Lillian L. Siu, Patricio Manque, and William C. Hahn Incorporating comprehensive tumor molecular profiling into the care of cancer patients Patricio Manque, Universidad Mayor, Santiago, Chile Clinical applications: Drug access and design of genotype-specific trials Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada Opportunities for translational and discovery research: Next-Gen genomics William C. Hahn, Dana-Farber Cancer Institute, Boston, Massachusetts Panel Discussion / Questions from audience Lillian L. Siu, Patricio Manque, and William C. Hahn 17:00-17:30 Welcome and Opening Remarks 17:30-18:00 Welcome Margaret Foti, American Association for Cancer Research, Philadelphia, Pennsylvania Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee Carlos Gil M. Ferreira, D or Institute for Research and Education, Rio de Janeiro, Brazil Plenary Session 1: Immune Checkpoints: Successes and What We Have Learned 18:00-19:30 Session Chair: Joao P.B. Viola, Brazilian National Cancer Institute, Rio de Janiero, Brazil Selective pressure by activated T cells identifies de novo and adaptive resistance mechanisms in melanoma Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, Massachusetts State of clinical success of immune checkpoints (new preclinical data on anti-pd-1 and ant PDL-1)

2 Cristina B. Bonorino, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil Abnormal ER stress responses as new immune checkpoints in cancer Juan R. Cubillos-Ruiz, Weill Cornell Medical College, New York, New York Opening Reception 19:45-21:30 Friday, May 5 Keynote Lecture 1 08:30-09:15 Session Chair: Carlos Gil M. Ferreira, D or Institute for Research and Education, Rio de Janeiro, Brazil Luisa L. Villa, Fundação Faculdade de Medicina de S Paulo, São Paulo, SP, Brazil 09:15-09:45 Plenary Session 2: Tumor Heterogeneity 09:45-10:45 Session Chair: Jorge S. Reis-Filho, Memorial Sloan Kettering Cancer Center, New York, New York The dynamics of cancer cell heterogeneity Guido Lenz, Federal University of Rio Grande do Sul, Porto Alegre, Brazil Intra-tumour genetic heterogeneity Jorge S. Reis-Filho, Memorial Sloan Kettering Cancer Center, New York, New York 10:45-11:00 Plenary Session 3: Hematological Malignancies 11:00-12:30 Session Chair: Eliana Abdelhay, Brazilian National Cancer Institute, Rio de Janiero, Brazil Epigenetic Mechanisms in Pathogenesis and Targeted Therapy for B-cell Lymphomas Ari M. Melnick, Weill Cornell Medical College, New York, New York

3 Clinical networking as a tool to improvement of leukemia care and research in developing countries: The experience of the International Consortium on Acute Leukemias (ICAL) Eduardo Magalhães Rego, University of São Paulo, Sao Paulo, Brazil Novel therapeutic targets in multiple myeloma Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts Poster Session A / Lunch 12:30-15:00 Plenary Session 4: Precision Medicine / Targeted and Combination Therapies / Drug Resistance 15:15-16:45 Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, Texas Overcoming drug resistance and tumor heterogeneity in gastrointestinal cancers Ryan B. Corcoran, Massachusetts General Hospital Cancer Center, Boston, Massachusetts Trever G. Bivona, University of California, San Francisco, California 16:45-17:00 Plenary Session 5: Liquid Biopsies/Organoids/PDX 17:00-18:30 Circulating tumor DNA is a liquid biopsy for precision medicine: Basic concepts Anamaria A. Camargo, Ludwig Institute for Research on Cancer, Sao Paulo, Brazil Cancer evolution as a therapeutic target Alberto Bardelli, University of Turin School of Medicine, Candiolo, Italy Patient-derived xenografts and organoids to predict therapeutic response for breast cancer patients Alana L. Welm, University of Utah Huntsman Cancer Institute,Salt Lake City, Utah

4 Saturday, May 6 Keynote Lecture 2 08:30-09:15 Session Chair: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee Speaker to be announced 09:15-09:45 Plenary Session 6: DNA Repair and PARP Inhibitors 09:45-11:15 Session Chair: Dyeison Antonow, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil Targeting DNA repair in cancer therapy Alan D. D'Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts Trapping PARP1 to kill cancer cells Yves G. Pommier, National Cancer Institute-CCR, Bethesda, Maryland Methods for defining DNA repair defects in human cancer Simon N. Powell, Memorial Sloan Kettering Cancer Center, New York, New York 11:15-11:30 Plenary Session 7: Hormone-Dependent Cancers and Steroid Receptors 11:30-13:00 Session Chair: Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil Lessons for ER+ breast cancer from neoadjuvant endocrine therapy trials Matthew J. Ellis, Baylor College of Medicine, Houston, Texas Targeting DNA repair dysfunction in prostate cancer Karen E. Knudsen, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania Samuel Aparicio, BC Cancer Research Centre, Vancouver, BC, Canada

5 Poster Session B / Lunch 13:00-15:00 Plenary Session 8: Oncogenes and Tumor Suppressors 15:15-16:45 Session Chair: Roger Chammas, University of São Paulo, Sao Paulo, Brazil Strategies to prevent and treat resistance to EGFR inhibitors in lung cancer Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, Massachusetts Tumor suppressor and tumor maintenance genes Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, New York Long noncoding RNA-mediated RNA editing as a new mechanism of tumor suppressor gene inactivation Emmanuel Dias-Neto, A.C. Camargo Cancer Center, São Paulo, Brazil 16:45-17:00 Plenary Session 9: Epigenetics 17:00-18:30 Daniel De Carvalho, Princess Margaret Cancer Centre, Toronto, ON, Canada Nilofer S. Azad, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, Maryland Defining cancer specific epigenomic signature associated with glioma progression Houtan Noushmehr, University of São Paulo, Ribeirao Preto, São Paulo, Brazil Closing Remarks 18:30-18:45 Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee Carlos Gil M. Ferreira, D or Institute for Research and Education, Rio de Janeiro, Brazil

SESSION 1: IMMUNE CHECKPOINTS: MECHANISMS AND THERAPEUTIC OPPORTUNITIES Grand Ballroom I/II

SESSION 1: IMMUNE CHECKPOINTS: MECHANISMS AND THERAPEUTIC OPPORTUNITIES Grand Ballroom I/II THURSDAY, SEPTEMBER 27 1200-1800 REGISTRATION Ballroom Foyer 1330-1430 WELCOME AND OPENING KEYNOTE LECTURE 1330-1340 Welcome from Scientific Committee Cochairs Carlos L. Arteaga, UT Southwestern Simmons